LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Phreesia Launches VoiceAI, a Conversational AI Solution to Transform Call Management in Healthcare

September 02, 2025 | Last Trade: US$24.19 1.29 -5.06
  • New offering enhances Phreesia’s existing platform, eliminating long hold times and ensuring every patient call is resolved

ALL-REMOTE COMPANY/WILMINGTON, Del. / Sep 02, 2025 / Business Wire / Phreesia, a leader in patient activation, today announced the launch of Phreesia VoiceAI, an always-on, intelligent AI phone solution purpose-built for healthcare. VoiceAI leverages advanced natural language processing and real-time workflow integration to help healthcare organizations manage high call volumes, streamline routine interactions and improve the patient experience—all without increasing staff workload.

VoiceAI allows patients to easily resolve common requests by using patients’ natural spoken language. VoiceAI then triages and routes those patient requests accordingly. Calls requiring clinical or administrative follow-up are seamlessly directed to the right team member.

  • Intelligent Triage: VoiceAI automatically identifies call intent using patient-spoken input and routes accordingly—no rigid phone trees or button-pushing.
  • Reliable Answers: AI responses are grounded in clinical rules and real-time scheduling logic.
  • Parallel Capacity: VoiceAI handles multiple calls simultaneously, reducing wait times and ensuring prompt responses.
  • Integrated Documentation: Staff can document interactions and access real-time patient information directly from a secure web app.*

*With supported EMRs

Phreesia VoiceAI supports the most common call types healthcare organizations handle every day—scheduling and referrals, prescription refills, clinical questions, and medical records requests—while also extending to urgent after-hours calls. Whether urgent or routine, calls are managed 24/7: urgent needs are routed directly to on-call physicians through a secure mobile app, while routine requests are captured and documented for timely follow-up.

“Phreesia has always been focused on making healthcare easier for patients, providers and staff,” said CEO Chaim Indig. “VoiceAI is the next big milestone in that journey and a logical extension of our platform, bringing the power of AI to one of the most resource-intensive parts of the practice—the phone—and delivering efficiency and better access for patients. We’re looking forward to continuing to add additional AI-enabled capabilities in the future.”

“The primary reason we chose Phreesia VoiceAI was the significant number of abandoned calls we were experiencing,” said Sumer Allen, Business Intelligence Services Manager at Urology Associates of Mobile. “Since implementation, our abandonment rate has dropped to zero, and patients truly appreciate receiving quick callbacks without the frustration of long wait times.”

About Phreesia

Phreesia is the trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page